Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Colistin/zidovudine - Helperby Therapeutics

Next Previous
Search
Drug Profile

Colistin/zidovudine - Helperby Therapeutics

Alternative Names: ARB-002/colistin; Azidothymidine/colistin - Helperby Therapeutics; Colistin methanosulphonate/ARB 002; HY-001; HY-002B1

Latest Information Update: 28 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helperby Therapeutics
  • Class Anti-infectives; Antibacterials; Antiretrovirals; Azides; Nucleosides; Peptide antibiotics; Polymixins; Small molecules; Urinary anti-infective agents
  • Mechanism of Action DNA synthesis inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Urinary tract infections
  • No development reported Intra-abdominal infections

Most Recent Events

  • 28 Jun 2022 No recent reports of development identified for phase-I development in Intra-abdominal-infections in United Kingdom (IV)
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Urinary-tract-infections(In volunteers) in United Kingdom (IV)
  • 01 Jul 2020 Phase-II clinical trials in Urinary tract infections (Complicated) (IV) in Poland (Helperby Therapeutics pipeline, June 2020)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top